How to buy Lipocine stock

Lipocine Inc is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Lipocine employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

Lipocine share price

Use our graph to track the performance of LPCN stocks over time.

Lipocine shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$0.55 - $2.42
50-day moving average	$1.53
200-day moving average	$1.55
Wall St. target price	$5.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.55

Buy Lipocine shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lipocine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lipocine Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lipocine financials

Gross profit TTM	$-5,053,695
Return on assets TTM	-49.98%
Return on equity TTM	-193.85%
Profit margin	0%
Book value	$0.22
Market capitalisation	$126.3 million

TTM: trailing 12 months

Shorting Lipocine shares

There are currently 3.5 million Lipocine shares held short by investors – that's known as Lipocine's "short interest". This figure is 14.5% down from 4.1 million last month.

There are a few different ways that this level of interest in shorting Lipocine shares can be evaluated.

Lipocine's "short interest ratio" (SIR)

Lipocine's "short interest ratio" (SIR) is the quantity of Lipocine shares currently shorted divided by the average quantity of Lipocine shares traded daily (recently around 4.1 million). Lipocine's SIR currently stands at 0.86. In other words for every 100,000 Lipocine shares traded daily on the market, roughly 860 shares are currently held short.

However Lipocine's short interest can also be evaluated against the total number of Lipocine shares, or, against the total number of tradable Lipocine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lipocine's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Lipocine shares in existence, roughly 40 shares are currently held short) or 0.0404% of the tradable shares (for every 100,000 tradable Lipocine shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lipocine.

Find out more about how you can short Lipocine stock.

Lipocine share dividends

We're not expecting Lipocine to pay a dividend over the next 12 months.

Have Lipocine's shares ever split?

Lipocine's shares were split on a 1:100 basis on 24 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.

Lipocine share price volatility

Over the last 12 months, Lipocine's shares have ranged in value from as little as $0.5479 up to $2.42. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.5312. This would suggest that Lipocine's shares are less volatile than average (for this exchange).

Lipocine overview

Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Frequently asked questions

• What percentage of Lipocine is owned by insiders or institutions?

  Currently 2.506% of Lipocine shares are held by insiders and 9.699% by institutions.

• How many people work for Lipocine?

  Latest data suggests 11 work at Lipocine.

• When does the fiscal year end for Lipocine?

  Lipocine's fiscal year ends in December.

• Where is Lipocine based?

  Lipocine's address is: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108

• What is Lipocine's ISIN number?

  Lipocine's international securities identification number is: US53630X1046

• What is Lipocine's CUSIP number?

  Lipocine's Committee on Uniform Securities Identification Procedures number is: 53630X104